Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 4/2016

01-08-2016 | Short Research Report

The pharmacokinetics of ampicillin–sulbactam in anuric patients: dosing optimization for prophylaxis during cardiovascular surgery

Authors: Yuta Yokoyama, Kazuaki Matsumoto, Kazuro Ikawa, Erika Watanabe, Hiroyuki Yamamoto, Yutaka Imoto, Norifumi Morikawa, Yasuo Takeda

Published in: International Journal of Clinical Pharmacy | Issue 4/2016

Login to get access

Abstract

Background The administration of antibiotic prophylaxis during cardiothoracic surgery can reduce the rate of surgical site infections. Trials of cardiothoracic antibiotic prophylaxis have found it to be beneficial in preventing postoperative wound infections. Objective To determine the more appropriate timing of repeated doses of ampicillin–sulbactam to maintain adequate antibiotic concentrations during cardiovascular surgery in anuric patients. Method Five adult anuric dialysis patients who received ampicillin–sulbactam during cardiovascular surgery at Kagoshima University Hospital, the total plasma concentrations of ampicillin and sulbactam were monitored after ampicillin (1 g)–sulbactam (0.5 g) administration. Pharmacokinetic parameters were estimated and used to predict the free plasma concentrations of ampicillin and sulbactam. Results The mean values for the volume of distribution, total clearance, elimination rate constant and the elimination half-life for ampicillin were 8.9 ± 2.4 L, 1.69 ± 0.93 L/h, 0.180 ± 0.059 h−1 and 4.23 ± 1.48 h, respectively. The pharmacokinetic parameters were similar to those of sulbactam. When ampicillin (1 g)–sulbactam (0.5 g) was intravenously administered at 8, 12 and 24 h intervals, the predicted free trough plasma concentrations of ampicillin were 28.72, 12.06 and 1.25 μg/mL, respectively. Conclusion We suggest that ampicillin (1 g)–sulbactam (0.5 g) should be intravenously administered every 12 h in order to maintain a free ampicillin concentration of more than 12 μg/mL in anuric patients during cardiovascular surgery.
Literature
1.
go back to reference Morikane K, Honda H, Yamagishi T, Suzuki S. Differences in risk factors associated with surgical site infections following two types of cardiac surgery in Japanese patients. J Hosp Infect. 2015;90:15–21.CrossRefPubMed Morikane K, Honda H, Yamagishi T, Suzuki S. Differences in risk factors associated with surgical site infections following two types of cardiac surgery in Japanese patients. J Hosp Infect. 2015;90:15–21.CrossRefPubMed
3.
go back to reference Yokoyama Y, Matsumoto K, Yamamoto H, Iguro Y, Imoto Y, Ikawa K, et al. Pharmacokinetics of ampicillin–sulbactam and the renal function-based optimization of dosing regimens for prophylaxis in patients undergoing cardiovascular surgery. J Infect Chemother. 2012;18:878–82.CrossRefPubMed Yokoyama Y, Matsumoto K, Yamamoto H, Iguro Y, Imoto Y, Ikawa K, et al. Pharmacokinetics of ampicillin–sulbactam and the renal function-based optimization of dosing regimens for prophylaxis in patients undergoing cardiovascular surgery. J Infect Chemother. 2012;18:878–82.CrossRefPubMed
4.
go back to reference Shimizu T. Studies on binding of cefazolin and other antibiotics. Jpn J Antibiot. 1974;27:296–301.PubMed Shimizu T. Studies on binding of cefazolin and other antibiotics. Jpn J Antibiot. 1974;27:296–301.PubMed
5.
go back to reference Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41:1159–66.CrossRefPubMed Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis. 2005;41:1159–66.CrossRefPubMed
6.
go back to reference Takesue Y, Watanabe A, Hanaki H, Kusachi S, Matsumoto T, Iwamoto A, et al. Nationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in Japan. J Infect Chemother. 2012;18:816–26.CrossRefPubMed Takesue Y, Watanabe A, Hanaki H, Kusachi S, Matsumoto T, Iwamoto A, et al. Nationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in Japan. J Infect Chemother. 2012;18:816–26.CrossRefPubMed
7.
go back to reference Blum RA, Kohli RK, Harrison NJ, Schentag JJ. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother. 1989;33:1470–6.CrossRefPubMedPubMedCentral Blum RA, Kohli RK, Harrison NJ, Schentag JJ. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis. Antimicrob Agents Chemother. 1989;33:1470–6.CrossRefPubMedPubMedCentral
8.
go back to reference Soto E, Shoji S, Muto C, Tomono Y, Marshall S. Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment. Br J Clin Pharmacol. 2014;77:509–21.CrossRefPubMedPubMedCentral Soto E, Shoji S, Muto C, Tomono Y, Marshall S. Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment. Br J Clin Pharmacol. 2014;77:509–21.CrossRefPubMedPubMedCentral
9.
go back to reference Gårdlund B. Postoperative surgical site infections in cardiac surgery—an overview of preventive measures. APMIS. 2007;115:989–95.CrossRefPubMed Gårdlund B. Postoperative surgical site infections in cardiac surgery—an overview of preventive measures. APMIS. 2007;115:989–95.CrossRefPubMed
Metadata
Title
The pharmacokinetics of ampicillin–sulbactam in anuric patients: dosing optimization for prophylaxis during cardiovascular surgery
Authors
Yuta Yokoyama
Kazuaki Matsumoto
Kazuro Ikawa
Erika Watanabe
Hiroyuki Yamamoto
Yutaka Imoto
Norifumi Morikawa
Yasuo Takeda
Publication date
01-08-2016
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 4/2016
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-016-0286-5

Other articles of this Issue 4/2016

International Journal of Clinical Pharmacy 4/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.